single-cell analysis

Sphere Fluidics' Cyto-Mine system automates single-cell analysis, sorting, imaging, and dispensing to help speed biopharmaceutical discovery.

CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.

In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.

The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.

This Week in Science

In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.

This Week in Nature

In Nature this week: extension to uncultivated virus genome reporting standards, multiplex orthogonal CRISPR-based genome editing approach, and more.

In Nucleic Acids Research this week: updated Aspergillus niger genome annotation, high-throughput sequencing strategy for profiling RNA structure, and more.

The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.

The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.

In a set of new studies, members of an international team mapped gene variation, expression, and regulatory interactions in developing and adult human brains.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.